P. Hoegen

发表

Adenovirus-mediated gene transfer of pathogen-associated molecular patterns for cancer immunotherapy

P. Erbs, S. Paul, H. Haegel, 2009, Cancer Gene Therapy.

An immunological role for the CD8 β-chain

J. Parnes, C. Wheeler, P. Hoegen, 1992, Nature.

Modification of tumor cells by a low dose of Newcastle Disease Virus.

V. Schirrmacher, E. Weber, P. Hoegen, 1988, European journal of immunology.

Inability of CD8α′polypeptides to associate with p56 lck correlates with impaired function in vitro and lack of expression in vivo

S. D. Gorman, R. Zamoyska, J. Bolen, 1989, Nature.

The r Integrin Chain Is a Ligand for r and o ~ 4 B 1 By

P. Altevogt, J. Lohr, M. Hubbe, 2003 .

Intra-pinna anti-tumor vaccination with self-replicating infectious RNA or with DNA encoding a model tumor antigen and a cytokine

P. Fournier, K. Chlichlia, V. Schirrmacher, 2000, Gene Therapy.

Synergistic role of type I interferons in the induction of protective cytotoxic T lymphocytes

P. Hoegen, 1995 .

Virus Superantigen Increases Tumor Resistance Loss of Endogenous Mouse Mammary Tumor

V. Schirrmacher, U. Beutner, M. Rocha, 1998 .

Active Specific Immunotherapy with Autologous Tumor Cell Vaccines Modified by Newcastle Disease Virus: Experimental and Clinical Studies

P. Schlag, K. Schumacher, V. Schirrmacher, 1989 .

Deficiency in T cell responses of human fetal lymph node cells: A lack of accessory cells

J. Krowka, P. Hoegen, S. Sarin, 1995, Immunology and cell biology.

Superiority of the ear pinna over muscle tissue as site for DNA vaccination

V. Schirrmacher, P. Hoegen, P. Foerg, 1998, Gene Therapy.

Modification of tumor cells by a low dose of Newcastle disease virus

H. Schild, V. Schirrmacher, P. Hoegen, 2004, Cancer Immunology, Immunotherapy.

Tumour‐Specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens

B. Gückel, V. Schirrmacher, P. Hoegen, 1993, Immunology and cell biology.

Antibody 12‐15 cross‐reacts with mouse Feγ receptors and CD2: study of thymus expression, genetic polymorphism and biosynthesis of the CD2 protein

P. Altevogt, V. Schirrmacher, P. Hoegen, 1989, European journal of immunology.

immune status studied with a lacZ transduced lymphoma Pattern and load of spontaneous liver metastasis dependent on host

A. Krüger, V. Schirrmacher, M. Rocha, 2011 .

Pattern and load of spontaneous liver metastasis dependent on host immune status studied with a lacZ transduced lymphoma

A. Krüger, V. Schirrmacher, M. Rocha, 1994 .

Scattered micrometastases visualized at the single‐cell level: Detection and re‐isolation of lacZ‐labeled metastasized lymphoma cells

A. Krüger, V. Schirrmacher, P. Hoegen, 1994, International journal of cancer.

Modification of tumor cells by a low dose of Newcastle disease virus. III. Potentiation of tumor-specific cytolytic T cell activity via induction of interferon-alpha/beta.

R. Zawatzky, V. Schirrmacher, P. Hoegen, 1990 .

Proteomic Prediction of Disease Outcome in Cancer

K. Günther, H. Lippert, M. Reymond, 2003 .

Specific eradication of micrometastases by transfer of tumour-immune T cells from major-histocompatibility-complex congenic mice

U. Zangemeister‐Wittke, V. Schirrmacher, P. Hoegen, 2005, Cancer Immunology, Immunotherapy.

The r Integrin Chain Is a Ligand for r and o~4B1 By Peter Altevogt,* Marcus Hubbe,* Michael tLuppert,*

J. Lohr, M. Humphries, M. Sammar, 1995 .

Promotion of experimental liver metastasis by tumor necrosis factor

A. Krüger, M. Hubbe, J. Rüschoff, 1995, International journal of cancer.

Synthetic biomimetic supra molecular Biovector (SMBV) particles for nasal vaccine delivery.

P. Hoegen, 2001 .

A clinically relevant HIV‐1 subunit vaccine protects rhesus macaques from in vivo passaged simian–human immunodeficiency virus infection

J. Heeney, Dominique Labbé, M. van der Kolk, 1998, AIDS.

Defining the critical hurdles in cancer immunotherapy

Zhigang Tian, Sylvia Janetzki, Cedrik M Britten, 2011, Journal of Translational Medicine.

The alpha 4 integrin chain is a ligand for alpha 4 beta 7 and alpha 4 beta 1

P. Altevogt, J. Lohr, M. Hubbe, 1995, The Journal of experimental medicine.

New antigens presented on tumor cells can cause immune rejection without influencing the frequency of tumor-specific cytolytic T cells.

P. Altevogt, V. Schirrmacher, P. von Hoegen, 1987, Cellular immunology.

Immunoresistant metastatic tumor variants can re‐express their tumor antigen after treatment with DNA methylation‐inhibiting agents

P. Altevogt, V. Schirrmacher, P. von Hoegen, 1986, International journal of cancer.

Adhesion versus coreceptor function of CD4 and CD8: role of the cytoplasmic tail in coreceptor activity.

J. Parnes, P. von Hoegen, M. Miceli, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Equivalence of human and mouse CD4 in enhancing antigen responses by a mouse class II-restricted T cell hybridoma

M. Schilham, J. Parnes, P. von Hoegen, 1989, The Journal of experimental medicine.

Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. I. Parameters for optimal therapeutic effects

R. Heicappell, V. Schirrmacher, P. von Hoegen, 1986, International journal of cancer.

Effects of mutagens on the immunogenicity of murine tumor cells: immunological and biochemical evidence for altered cell surface antigens.

P. Altevogt, V. Schirrmacher, P. von Hoegen, 1985, Cancer research.